The Children's Oncology Group (COG) is the largest childhood cancer research organization in the world and encompasses 216 pediatric cancer programs with a mission to cure and prevent childhood and adolescent cancer through scientific discovery and compassionate care. The COG was formed from the merger of four legacy pediatric cooperative groups in 2000. The COG Community Clinical Oncology Program (CCOP) Research Base was funded in 2002 as a Treatment and Cancer Prevention and Control CCOP Research Base. The COG CCOP Research Base supports 19 CCOPs and 7 Minority-Based CCOPs for participation on innovative clinical and translational research studies for cancer treatment, prevention and control. The involvement of community-based pediatric oncologists and other health professionals in the research mission of the COG is pivotal. CCOPs provide an important mechanism to evaluate advanced treatments administered in community settings and broaden the population-base for protocol participation. The COG makes available to CCOPs/Minority-Based CCOPs current treatment protocols with access to investigational agents and special centralized reference laboratories, quality assurance infrastructure and statistical support, thus promoting high quality cancer care for young persons treated in community settings. The COG provides continuing training and support for CCOP personnel and ensures that all CCOPs maintain high quality assurance standards for membership, accrual, and institutional performance. COG conducts clinical trials to define optimal treatments for children and adolescents with cancer, with a focus on addressing the unique needs of children afflicted with cancer. The Cancer Control Committee develops studies that focus on identifying, preventing or ameliorating treatment-related sequelae and improving the quality of life for children and adolescents with cancer and their families.

Public Health Relevance

The mission of COG is to cure and prevent childhood and adolescent cancer and is unique in addressing their specific needs. The CCOPs affiliated with COG and its legacy groups have a significant impact on decreasing the burden of childhood cancer and its long-term effects on patients and their families.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-B (J1))
Program Officer
O'Mara, Ann M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Children's Hospital of Philadelphia
United States
Zip Code
Dupuis, L Lee; Kelly, Kara M; Krischer, Jeffrey P et al. (2018) Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial. Cancer 124:1188-1196
Zheng, Daniel J; Lu, Xiaomin; Schore, Reuven J et al. (2018) Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. Cancer 124:571-579
Alexander, Sarah; Fisher, Brian T; Gaur, Aditya H et al. (2018) Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. JAMA 320:995-1004
Knight, Kristin R; Chen, Lu; Freyer, David et al. (2017) Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. J Clin Oncol 35:440-445
Haase, Joan E; Kintner, Eileen K; Robb, Sheri L et al. (2017) The Resilience in Illness Model Part 2: Confirmatory Evaluation in Adolescents and Young Adults With Cancer. Cancer Nurs 40:454-463
Freyer, David R; Chen, Lu; Krailo, Mark D et al. (2017) Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18:63-74
Viola, Adrienne; Balsamo, Lyn; Neglia, Joseph P et al. (2017) The Behavior Rating Inventory of Executive Function (BRIEF) to Identify Pediatric Acute Lymphoblastic Leukemia (ALL) Survivors At Risk for Neurocognitive Impairment. J Pediatr Hematol Oncol 39:174-178
Landier, Wendy; Hageman, Lindsey; Chen, Yanjun et al. (2017) Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. J Clin Oncol 35:1730-1736
Landier, Wendy; Chen, Yanjun; Hageman, Lindsey et al. (2017) Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study. Blood 129:1919-1926
Balsamo, Lyn M; Sint, Kyaw J; Neglia, Joseph P et al. (2016) The Association Between Motor Skills and Academic Achievement Among Pediatric Survivors of Acute Lymphoblastic Leukemia. J Pediatr Psychol 41:319-28

Showing the most recent 10 out of 66 publications